Trial Profile
Study of lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Oct 2018
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2018 Neew trial record.